J. Czepiel, M. Rajzer, G. Bilo, G. Parati, G. Biesiada, D. Cibor, Ewelina Pitera, P. Wołkow, M. Michalak, A. Garlicki
{"title":"The Association Between Chronic Hepatitis B, Chronic Hepatitis C, Sustained Liver Damage, and Features of Increased Cardiovascular Risk","authors":"J. Czepiel, M. Rajzer, G. Bilo, G. Parati, G. Biesiada, D. Cibor, Ewelina Pitera, P. Wołkow, M. Michalak, A. Garlicki","doi":"10.3409/FB_69-1.03","DOIUrl":null,"url":null,"abstract":"It is thought that chronic liver disease affects a person's risk of cardiovascular disease (CVD) development. The aim of this study was to assess the effect of Chronic Hepatitis B (HBV) infection, Chronic Hepatitis C (HCV) infection, and liver damage on cardiovascular risk and selected\n vascular parameters contributing to CVD risk. This case-control study included a group of 114 patients composed of 34 patients with HBV, 35 patients with HCV, and 45 patients as the control group. Cardiovascular risk was assessed by analyzing classic risk factors, and the SCORE system. The\n following arterial properties were analyzed using applanation tonometry with SphygmoCor Vx technology: central systolic blood pressure (cSBP), central pulse pressure, augmentation pressure, augmentation index, and carotid-femoral pulse wave velocity (PWV). Asymmetric dimethyloarginine (ADMA)\n blood levels were analyzed using ELISA as a marker of vascular function. In a univariable analysis we found no significant differences between the hepatitis B, hepatitis C, and control groups in terms of PWV (respectively: median 7.2 [Q25-Q75 6.4-8.5], 7.3 [6.9-8.7], 7.8 [6.5-8.9]), cSBP (115\n [109-126], 118 [107-123], 116 [107-129]), ADMA (0.52 [0.47-0.60], 0.53 [0.45-0.62], 0.58 [0.51-0.63]), SCORE (0 [0-1], 0 [0-2], 0 [0-2]). No significant differences in cardiovascular variables were observed between cirrhotic and non-cirrhotic patients. A multivariable analysis confirmed the\n above findings. (PWV, p=0 . 29; cSBP, p=0.26; ADMA, p=0.19). We concluded that chronic hepatitis B or C was not independently associated with an adverse cardiovascular risk profile nor with an unfavorable pattern of vascular parameters contributing to CVD risk in our study population, even\n in the case of liver cirrhosis. The same was true for blood ADMA levels.","PeriodicalId":50438,"journal":{"name":"Folia Biologica-Krakow","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Biologica-Krakow","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3409/FB_69-1.03","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
It is thought that chronic liver disease affects a person's risk of cardiovascular disease (CVD) development. The aim of this study was to assess the effect of Chronic Hepatitis B (HBV) infection, Chronic Hepatitis C (HCV) infection, and liver damage on cardiovascular risk and selected
vascular parameters contributing to CVD risk. This case-control study included a group of 114 patients composed of 34 patients with HBV, 35 patients with HCV, and 45 patients as the control group. Cardiovascular risk was assessed by analyzing classic risk factors, and the SCORE system. The
following arterial properties were analyzed using applanation tonometry with SphygmoCor Vx technology: central systolic blood pressure (cSBP), central pulse pressure, augmentation pressure, augmentation index, and carotid-femoral pulse wave velocity (PWV). Asymmetric dimethyloarginine (ADMA)
blood levels were analyzed using ELISA as a marker of vascular function. In a univariable analysis we found no significant differences between the hepatitis B, hepatitis C, and control groups in terms of PWV (respectively: median 7.2 [Q25-Q75 6.4-8.5], 7.3 [6.9-8.7], 7.8 [6.5-8.9]), cSBP (115
[109-126], 118 [107-123], 116 [107-129]), ADMA (0.52 [0.47-0.60], 0.53 [0.45-0.62], 0.58 [0.51-0.63]), SCORE (0 [0-1], 0 [0-2], 0 [0-2]). No significant differences in cardiovascular variables were observed between cirrhotic and non-cirrhotic patients. A multivariable analysis confirmed the
above findings. (PWV, p=0 . 29; cSBP, p=0.26; ADMA, p=0.19). We concluded that chronic hepatitis B or C was not independently associated with an adverse cardiovascular risk profile nor with an unfavorable pattern of vascular parameters contributing to CVD risk in our study population, even
in the case of liver cirrhosis. The same was true for blood ADMA levels.
人们认为慢性肝病会影响一个人患心血管疾病(CVD)的风险。本研究的目的是评估慢性乙型肝炎(HBV)感染、慢性丙型肝炎(HCV)感染和肝损伤对心血管风险的影响,以及与心血管风险相关的选定血管参数。本病例对照研究纳入114例患者,其中34例HBV患者,35例HCV患者,45例为对照组。通过分析经典危险因素和SCORE系统评估心血管风险。采用sphygmomoor Vx技术平压血压计分析以下动脉特性:中心收缩压(cSBP)、中心脉压、增强压、增强指数和颈-股脉波速度(PWV)。不对称二甲基精氨酸(ADMA)血药浓度作为血管功能指标,采用ELISA法进行分析。在单变量分析中,我们发现乙肝、丙肝和对照组在PWV(分别为:中位数7.2 [Q25-Q75 6.4-8.5]、7.3[6.9-8.7]、7.8[6.5-8.9])、cSBP(115[109-126]、118[107-123]、116[107-129])、ADMA(0.52[0.47-0.60]、0.53[0.45-0.62]、0.58[0.51-0.63])、SCORE(0[0-1]、0[0-2]、0[0-2])方面无显著差异。肝硬化和非肝硬化患者的心血管变量无显著差异。多变量分析证实了上述发现。p=0。29日;cSBP, p = 0.26;ADMA, p = 0.19)。我们的结论是,慢性乙型肝炎或丙型肝炎与不良心血管风险状况没有独立关联,也没有与导致心血管疾病风险的不利血管参数模式相关,即使在肝硬化的情况下也是如此。血液ADMA水平也是如此。
期刊介绍:
Folia Biologica (Kraków) is an international online open access journal accepting original scientific articles on various aspects of zoology: phylogeny, genetics, chromosomal studies, ecology, biogeography, experimental zoology and ultrastructural studies. The language of publication is English, articles are assembled in four issues per year.